A look at the plasma protein therapeutics pipeline makes it clear that the wide variety of application areas will drive the growth of this market. According to a pipeline analysis of the plasma protein therapeutics market conducted by Transparency Market Research as part of a larger study of this market, therapies in phase I and phase II of clinical trials are being developed for conditions ranging from post-polio syndrome and myasthenia gravis to kidney failure and diabetes mellitus. If these studies yield the desired results and culminate in successfully commercialized therapies, the global plasma protein therapeutics market will see a massive revenue boost in the long term.
Browse the full Global Plasma Protein Therapeutics Market Report:http://www.mrrse.com/plasma-protein-therapeutics-market
The near-term growth of this market is already on a positive footing with TMR expecting global plasma protein therapeutics market revenues to touch US$19.56 bn by the end of 2016 and further cross US$31.84 bn by 2024.
Unmistakable Opportunities are Emerging in the Albumin Products Segment
Among all product types that have a visible impact on revenue growth in the global plasma protein therapeutics market, immunoglobulins represent a major share in revenues as far as plasma derived products go. The treatment plans of several patients worldwide with neurological conditions and primary immunodeficiency diseases now include intravenous immunoglobulin (IVIG). Factors such as this one will help the global plasma protein therapeutics market notch a CAGR of 7.8% between 2014 and 2024.
However, with a CAGR of over 9.0%, the albumin segment is expected to show greater promise in terms of revenue growth through the forecast period. This change is occurring primarily on account of the use of human albumin in as a sealant in surgeries, in vaccines, as a coating for medical devices, and also in the form of a drug formulation agent.
Regulatory Will to Bring Biosimilars to Scale to Create Positive Change in Plasma Protein Therapeutics Market Dynamics
The U.S. Food and Drug Administration is making an attempt to launch a new process that will help bring biosimilars to the market faster. These efforts are part of the Biologics Price Competition and Innovation Act of 2009. The act itself was a component in the March 2010 healthcare reform law and it ups the possibilities of bringing more affordable drugs to the market within abbreviated timelines. With this, the overall affordability of healthcare in the United States is expected to receive a definite boost. This trend will augur well for the growth of the overall plasma protein therapeutics market, market watchers expect.
Browse the full Press Release of Global Plasma Protein Therapeutics Market at http://www.mrrse.com/global-plasma-protein-therapeutics-market
Although the U.S. is yet to see a concrete regulatory framework for the approval of biosimilars, more clarity in this space is expected soon. This change is expected to be prove especially beneficial for the growth of the primary immunodeficiency diseases market, which has proven extremely valuable for companies in the plasma protein therapeutics market in recent years.
While the prospects are definitely bright in the United States, the same cannot be immediately said about markets in Latin America and Asia Pacific. There is still some ground to be covered in the latter markets especially because consumers still perceive plasma protein therapeutics as being expensive and tend to reject them.